BridgeBio Pharma Inc (BBIO) Stock Price & News

Q3 2026 earnings • in 4 days

See details

BBIO:NASDAQ

BridgeBio Pharma Inc

$68.56

+0.65%

(+0.44) 1D

$68.56

0.00% (0.00)

After hours

Closed: Oct 23, 4:00:01 PM GMT-4 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for BBIO...

Open

$67.69

High

$68.86

Low

$67.02

Mkt. cap

13.40B

Avg. vol.

2.91M

Volume

2.40M

52-wk high

$93.42

52-wk low

$54.23

EPS

-$3.57

Beta

0.97

Shares outstanding

195.49M

No. of employees

Open

$67.69

High

$68.86

Low

$67.02

Mkt. cap

13.40B

Avg. vol.

2.91M

Volume

2.40M

52-wk high

$93.42

52-wk low

$54.23

EPS

-$3.57

Beta

0.97

Shares outstanding

195.49M

No. of employees

Related stocks

RVMD

Revolution Medicines Inc

$186.99

-0.37%

ALNY

Alnylam Pharmaceuticals, Inc.

$224.03

-1.43%

NBIX

Neurocrine Biosciences, Inc

$142.70

-0.41%

MDGL

Madrigal Pharmaceuticals Inc

$434.24

-4.21%

News stories

From web sources and news partners

Yahoo Finance

33 minutes ago

Up 35%, How Long Can Coca-Cola Continue Crushing the S&P 500?

Benzinga

13 minutes ago

S&P 500, VOO, and SPY Outlook: What Investors Need to Watch This Week

Traders Union

1 hour ago

Dow gains almost 4% following Gold window closing, Spina notes

Stocktwits

3 hours ago

Apollo’s Torsten Slok Warns AI Has Delivered ‘Zero Financial Payoff’ Outside Tech — 'AI Story Will Be Decided In The S&P 493, Not The Mag 7'

About BridgeBio Pharma Inc

CEONeil Kumar

Employees1K

Founded2015

HeadquartersPalo Alto, California, United States

SectorBiotechnology

Websitebridgebio.com

Analyst ratings

Based on 18 analysts giving stock ratings to BBIO in the past 3 months

Strong buy

Buy

Hold

Sell

12-month forecast

Based on 18 Wall Street analysts offering 12 month price targets for BBIO in the last 3 months.

Highest

Current $68.56

$156.00 (+127.54%)

Average

$109.65 (+59.93%)

Lowest

$87.00 (+26.90%)

Analyst	Recommendation	Action	Price target	Projected	Date
Sean Laaman Morgan Stanley	Buy	Maintained	$87.00	+26.9%	10/22/2026
Biren Amin Piper Sandler	Buy	Maintained	$120.00	+75%	10/19/2026
Jason Zemansky Bank of America Securities	Buy	Reiterated	$102.00	+48.8%	10/19/2026
Eric Joseph Citi	Hold	Maintained	$91.00	+32.7%	10/20/2026
Yanan Zhu Wells Fargo	Buy	Maintained	$102.00	+48.8%	10/15/2026
Joon Lee UBS	Buy	Initiated	$92.00	+34.2%	10/16/2026
Ram Selvaraju H.C. Wainwright	Buy	Reiterated	$120.00	+75%	10/15/2026
Luca Issi RBC Capital	Buy	Maintained	$100.00	+45.9%	10/08/2026
Whitney Ijem Canaccord Genuity	Buy	Maintained	$106.00	+54.6%	10/06/2026
Eliana Merle Barclays	Buy	Maintained	$156.00	+127.5%	10/07/2026
Myles Minter William Blair	Buy	Reiterated	-	-	10/06/2026
Tyler Van Buren TD Cowen	Buy	Reiterated	$110.00	+60.4%	09/24/2026
Cory Kasimov Evercore ISI	Buy	Maintained	$130.00	+89.6%	09/14/2026
Salim Syed Mizuho Securities	Buy	Maintained	$110.00	+60.4%	08/31/2026
Andrew Tsai Jefferies	Buy	Maintained	$110.00	+60.4%	08/31/2026
Joshua Schimmer Cantor Fitzgerald	Buy	Maintained	$110.00	+60.4%	08/29/2026
Anupam Rama J.P. Morgan	Buy	Reiterated	$111.00	+61.9%	08/12/2026
Danielle Brill Truist Financial	Buy	Maintained	$107.00	+56.1%	08/12/2026
Derek Archila Wells Fargo	Buy	Reiterated	$102.00	+48.8%	08/11/2026
Unknown Analyst Wells Fargo	Buy	Reiterated	$102.00	+48.8%	08/11/2026
Tiago Fauth Raymond James	Buy	Maintained	$98.00	+42.9%	06/17/2026
Martin Auster Raymond James	Hold	Downgraded	-	-	05/26/2026
Unknown Analyst Citi	Hold	Initiated	-	-	05/19/2026
William Pickering Bernstein	Buy	Reiterated	$114.00	+66.3%	05/08/2026
Paul Choi Goldman Sachs	Buy	Maintained	$116.00	+69.2%	05/08/2026
Matt Phipps William Blair	Buy	Reiterated	-	-	05/02/2026
Lisa Walter RBC Capital	Buy	Initiated	$100.00	+45.9%	04/08/2026
Trevor Allred Oppenheimer	Buy	Maintained	$81.00	+18.1%	02/25/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	120.70M	154.18M	194.52M	243.68M
Cost of goods sold	6.56M	8.11M	9.94M	15.05M
Cost of revenue	6.56M	8.11M	9.94M	15.05M
Research and development expenses	112.87M	116.42M	126.64M	149.45M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	137.62M	158.08M	163.90M	186.26M
Operating expense	250.50M	274.50M	290.53M	335.71M
Total operating expenses	257.06M	282.61M	300.47M	350.76M
Operating income	-136.36M	-128.43M	-105.96M	-107.08M
Other non operating income	16.46M	11.82M	4.25M	5.59M
EBT including unusual items	-186.48M	-194.76M	-166.56M	-155.89M
EBT excluding unusual items	-177.64M	-183.62M	-166.56M	-155.89M
Income tax expense	-1.54M	-120.00K	-	-
Effective tax rate	0.83%	0.06%	-	-
Other operating expenses	-	-	-	-
Net income	-182.74M	-192.86M	-164.04M	-152.22M
Net profit margin	-151.40%	-125.09%	-84.33%	-62.47%
Earnings per share	-0.72	-0.94	-0.84	-0.78
Interest and investment income	6.24M	4.33M	6.25M	6.66M
Interest expense	-48.15M	-50.31M	-52.82M	-54.62M
Net interest expenses	-41.91M	-45.98M	-46.57M	-47.96M
Depreciation and amortization charges	-	-	-	-
EBITDA	-134.96M	-127.00M	-104.77M	-106.03M
Gain or loss from assets sale	-	-	-	-

Ask anything